Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nasafytol is an oral combination dietary supplement containing **quercetin**, **curcumin** (from turmeric extract), and **vitamin D3**. It is designed to support the immune system, respiratory function, and reduce allergic symptoms. Recent clinical studies in adults—especially among those with COVID-19—have shown that Nasafytol can expedite symptom resolution and viral clearance when used as an adjunct to standard medical care. Its mechanism of action includes providing synergistic **anti-inflammatory**, **antioxidant**, **immunomodulatory**, and **antiviral** effects through its components: - Quercetin is a polyphenol known for broad-spectrum anti-viral, anti-inflammatory, and antioxidant effects. - Curcumin exerts anti-inflammatory and antioxidant effects, and supports lung and immune health. - Vitamin D3 modulates immune response and supports normal immune system function[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nasafytol.